Merck Canada And The Pan-Canadian Pharmaceutical Alliance Have Completed Negotiations For WELIREG, Indicating The Next Step Will Involve Provincial And Territorial Governments, And Federal Drug Programs Implementing Reimbursement For Their Respective...
Merck Canada And The Pan-Canadian Pharmaceutical Alliance Have Completed Negotiations For WELIREG, Indicating The Next Step Will Involve Provincial And Territorial Governments, And Federal Drug Programs Implementing Reimbursement For Their Respective...
Merck Canada And The Pan-Canadian Pharmaceutical Alliance Have Completed Negotiations For WELIREG, Indicating The Next Step Will Involve Provincial And Territorial Governments, And Federal Drug Programs Implementing Reimbursement For Their Respective Jurisdictions
默沙東加拿大和泛加藥品聯盟已完成對WELIREG的談判，接下來的步驟將涉及各省和地方政府以及聯邦藥品計劃在各自的管轄範圍內實施償還。
Approved indications include the treatment of adult patients with von Hippel-Lindau (VHL) disease for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery
批准適應症包括對成年患者進行von Hippel-Lindau（VHL）病的治療，以及相關的非轉移性腎細胞癌（RCC）、中樞神經系統（CNS）血管母細胞瘤血管球瘤（Hemangioblastomas）或非轉移性胰腺神經內分泌腫瘤（pNET），不需要立即手術。
KIRKLAND, QC, Sept. 5, 2024 /CNW/ - Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for WELIREG (belzutifan) on August 30th. The pCPA negotiates on behalf of the provinces, territories, and federal drug programs, serving as a critical step in bringing WELIREG closer to public reimbursement.
默沙東（紐交所代碼：MRK）於2024年9月5日在加拿大魁北克市公告，該公司已與泛加藥品聯盟（pCPA）就WELIREG（belzutifan）成功完成談判。泛加藥品聯盟代表各省、地區和聯邦藥品計劃進行談判，這是將WELIREG更接近公共償還的重要一步。
Reaching this significant milestone is the outcome of close collaboration with the pCPA and highlights the necessity to progress quickly towards public reimbursement. The next step will involve provincial and territorial governments, and federal drug programs implementing reimbursement for their respective jurisdictions.
達到這一重要里程碑是與泛加藥品聯盟緊密合作的結果，並突顯了快速推進公共償還的必要性。下一步將涉及各省和地方政府以及聯邦藥品計劃在各自的管轄範圍內實施償還。
譯文內容由第三人軟體翻譯。